Valuation: Mangalam Drugs & Organics Limited

Market Cap 507M 5.29M 4.61M 4.36M 3.96M 7.41M 7.44M 51.98M 20.1M 258M 19.89M 19.44M 825M P/E 2025
17.5x
P/E 2026 -0.99x
Enterprise Value 1.63B 16.99M 14.8M 14.01M 12.73M 23.78M 23.89M 167M 64.52M 827M 63.84M 62.42M 2.65B EV / Sales 2025
0.66x
EV / Sales 2026 0.67x
Free-Float
62.31%
Yield 2025 *
-
Yield 2026 -
08-17 Mangalam Drugs and Organics Limited Discloses Default on Bank Loan Accounts with Bank of Baroda and Bank of Maharashtra CI
08-12 Mangalam Drugs & Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06-17 Mangalam Drugs and Organics Ltd. Defaults on Loan Obligations to Bank of Baroda and Bank of Maharashtra CI
05-14 Mangalam Drugs & Organics Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
04-17 Mangalam Drugs & Organics Limited Announces Resignation of Anuradha Pandey as Company Secretary & Compliance Officer, Effective March 29, 2026 CI
04-16 Mangalam Drugs and Organics Limited Defaults on Loan Obligations Exceeding 30 Days with INR 95.197 Million to Bank of Maharashtra and INR 60.608 Million to Bank of Baroda CI
03-26 Mangalam Drugs and Organics Limited Appoints Shweta Patel as Company Secretary & Compliance Officer, Effective April 1, 2026 CI
03-17 Mangalam Drugs and Organics Limited Reports Loan Defaults Exceeding 30 Days on Bank Borrowings CI
03-17 Mangalam Drugs and Organics Limited Defaults on Loan Obligations to Bank of Maharashtra and Bank of Baroda CI
03-17 Mangalam Drugs and Organics Limited Defaults on Bank Loan Obligations Exceeding 30 Days with INR 70.705 Million to Bank of Maharashtra and INR 44.677 Million to Bank of Baroda CI
03-17 Mangalam Drugs and Organics defaults on loan obligations to Bank of Baroda, Bank of Maharashtra RE
02-06 Mangalam Drugs and Organics names Jeevan M. Dalvi as CFO RE
02-06 Mangalam Drugs and Organics Limited Approves the Appointment of Jeevan Mukund Dalvi as Chief Financial Officer, Effective February 6, 2026 CI
1 day+5.21%
1 week-7.34%
Current month+6.14%
1 month+20.36%
3 months+12.07%
6 months+8.50%
Current year+22.15%
1 week 31.36
Extreme 31.36
36.87
1 month 26.56
Extreme 26.56
38.25
Current year 25.7
Extreme 25.7
54.51
1 year 22.7
Extreme 22.7
85.99
3 years 22.7
Extreme 22.7
144.65
5 years 22.7
Extreme 22.7
172.65
10 years 20.4
Extreme 20.4
225.9
Manager TitleAgeSince
Chief Executive Officer 72 30/09/2011
Director of Finance/CFO - 06/02/2026
Compliance Officer 27 01/04/2026
Director TitleAgeSince
Chairman 72 02/02/2010
Director/Board Member 75 05/02/2015
Director/Board Member 38 28/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
+5.21%-7.34%-55.07%-67.22% 5.29M
-0.79%+0.70%+12.39%+61.44% 46.78B
-0.27%-1.15%+37.03%+101.17% 37.88B
+1.74%+3.14%+10.15%+79.39% 11.82B
+0.23%+1.00%-12.58%+11.21% 11.61B
0.00%+0.57%+18.78%+148.82% 9.12B
+1.43%+2.32%+29.48%+38.91% 7.38B
-0.58%-0.65%+13.99%+182.24% 7.12B
+0.50%+3.58%+39.71%-17.89% 7.21B
+1.38%-2.74%-42.62%+6.68% 4.99B
Average +0.89%-0.22%+5.13%+54.47% 14.39B
Weighted average by Cap. -0.05%+0.02%+17.50%+73.80%

Financials

2025 2026
Net sales 3.18B 33.16M 28.88M 27.34M 24.84M 46.4M 46.63M 326M 126M 1.61B 125M 122M 5.17B 2.32B 24.24M 21.11M 19.98M 18.15M 33.91M 34.08M 238M 92.02M 1.18B 91.05M 89.03M 3.78B
Net income 67.21M 702K 611K 578K 526K 982K 987K 6.89M 2.66M 34.16M 2.64M 2.58M 109M -444M -4.64M -4.04M -3.82M -3.47M -6.49M -6.52M -45.52M -17.6M -226M -17.42M -17.03M -722M
Net Debt 936M 9.78M 8.52M 8.06M 7.32M 13.68M 13.75M 96M 37.12M 476M 36.73M 35.91M 1.52B 1.12B 11.7M 10.19M 9.64M 8.76M 16.37M 16.45M 115M 44.42M 569M 43.95M 42.97M 1.82B
Logo Mangalam Drugs & Organics Limited
Mangalam Drugs and Organics Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Under the Company's Fight Malaria Program, it supplies anti-malaria APIs worldwide. Its products include API, intermediates and specialty chemicals. Its API products include acyclovir, amodiaquine, artemether, artesunate, atazanavir sulfate, bisoprolol fumarate, chloroquine phosphate, furosemide and dolutegravir sodium. The Company's intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine; 4,7- dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base, and tenofovir disoproxil base. Its specialty chemical products include L (+)-menthol; 2,3-dihydrophthalazine-1,4-dione or phthalazine-1,4-dione, and 4-cynoethyl-2-methyl phenol. Its pipeline APIs (under development) include Ganaplacide (IH), Tafenoquine Succinate (IH) and Pretomanid (IH). Its pipeline APIs (developed for research and development) is Bictegravir Na (IH).
Employees
319
Date Price Change Volume
18/09/26 33.70 +5.21% 13,457
17/09/26 ₹32.03 +0.09% 2,904
16/09/26 ₹32.00 -3.88% 7,346
15/09/26 ₹33.29 -8.47% 20,433
11/09/26 ₹36.37 +4.42% 37,817
  1. Stock Market
  2. Stocks
  3. MANGALAM Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!